Want to see HURA full AI Analyst Report?
HURA Stock Chart & Stats
$2.04
-$0.03(-0.55%)
At close: 4:00 PM EST
$2.04
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$0.41 - $3.43
Previous CloseN/A
Volume116.05K
Average Volume (3M)240.85K
Market Cap
$138.92M
Enterprise Value$152.96M
Total Cash (Recent Filing)$995.98K
Total Debt (Recent Filing)$407.02K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Nov 13, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding63,726,616
10 Day Avg. Volume288,953
30 Day Avg. Volume240,846
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.31
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.52K
Enterprise Value/Ebitda-5.20
Forecast
1Y Price Target
$9.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage and positive equity provide a stronger financial foundation than the company’s operating results alone would suggest. This can preserve flexibility to fund clinical development, negotiate financing, and absorb volatility without the immediate pressure of a heavily debt-funded capital structure.
Long-term Capital AccessThe five-year revolving credit facility gives TuHURA access to structured capital for business needs beyond the immediate reporting period. Continued availability can support development activities and operational planning, although the facility remains a financing resource rather than internally generated cash.
Focused Oncology StrategyTuHURA is concentrated on important oncology treatment challenges, including resistance to immune checkpoint inhibitors and the need to strengthen anti-tumor immunity. A focused clinical strategy can help direct scarce resources toward defined therapeutic goals and differentiated development opportunities.
Bears Say
No Commercial RevenueZero revenue means TuHURA has not yet demonstrated commercial product demand or an operating revenue base. Until a candidate reaches commercialization, the company’s ability to fund research and clinical programs depends on financing and successful development milestones rather than recurring customer cash flow.
Widening LossesLosses have expanded materially over the periods provided, showing that operating expenses continue to rise without offsetting revenue. Persistent and widening deficits can reduce financial flexibility, increase future capital requirements, and make progress toward sustainable earnings dependent on successful clinical and commercial execution.
Persistent Cash BurnHeavy negative operating and free cash flow indicates that ongoing activities consume substantial cash and are not self-funding. The trend implies continued reliance on external financing to sustain operations, while repeated borrowing or equity funding can increase obligations and constrain future capital allocation.
TuHURA Biosciences News
HURA FAQ
What was TuHURA Biosciences’s price range in the past 12 months?
TuHURA Biosciences lowest stock price was $0.41 and its highest was $3.43 in the past 12 months.
What is TuHURA Biosciences’s market cap?
TuHURA Biosciences’s market cap is $138.92M.
When is TuHURA Biosciences’s upcoming earnings report date?
TuHURA Biosciences’s upcoming earnings report date is Nov 13, 2026 which is in 19 days.
How were TuHURA Biosciences’s earnings last quarter?
TuHURA Biosciences released its earnings results on Aug 14, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.013.
Is TuHURA Biosciences overvalued?
According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued.
Does TuHURA Biosciences pay dividends?
TuHURA Biosciences does not currently pay dividends.
What is TuHURA Biosciences’s EPS estimate?
TuHURA Biosciences’s EPS estimate is -0.14.
How many shares outstanding does TuHURA Biosciences have?
TuHURA Biosciences has 63,726,616 shares outstanding.
What happened to TuHURA Biosciences’s price movement after its last earnings report?
TuHURA Biosciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went up 7.391%.
Which hedge fund is a major shareholder of TuHURA Biosciences?
Currently, no hedge funds are holding shares in HURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TuHURA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (341.18% Upside)
$9.00 (341.18% Upside)
Blogger Sentiment
Bullish
HURA Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 82.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.24%
12-Months-Change
Fundamentals
Return on Equity
-154.32%
Trailing 12-Months
Asset Growth
-8.30%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TuHURA Biosciences
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
HURA Stock 12 Month Forecast
Average Price Target
$9.00
▲(341.18% Upside)
Technical Analysis
Agenus
―
Inovio Pharmaceuticals
―
Skye Bioscience
―
Biomea Fusion
―
Cognition Therapeutics
―
Ownership Overview
3.52% Insiders
5.01% Mutual Funds
0.05% Other Institutional Investors
87.73% Public Companies and
Individual Investors